Proton Therapy Carries Precise, Potent Punch Against Cancers for Patients at The Children's Hospital of Philadelphia

PHILADELPHIA, May 27 /PRNewswire-USNewswire/ -- The Children's Hospital of Philadelphia announces the availability of proton therapy, a precise form of cancer radiation that offers potentially life-changing benefits to children with brain tumors and other solid tumors. The Hospital's Cancer Center has recently begun using proton treatment at the new Roberts Proton Therapy Center, a cutting-edge radiation oncology facility located across the street from Children's Hospital in Penn Medicine's Perelman Center for Advanced Medicine.

With a child diagnosed with a brain tumor, parents often face a cruel dilemma. Conventional radiation treatment that offers survival often risks severe side effects, including damage to surrounding healthy tissue, as well as impairments to hearing, vision, growth and cognition. The after-effects may impede a child's daily life and may carry the prospect of lifelong disability and dependence. In fact, the side effects are potentially devastating enough that conventional radiation therapy is not given to children under age two.

The Roberts Proton Therapy Center is the only proton therapy facility in the country conceived with pediatric patients in mind from the earliest planning stages. Children who receive proton therapy in this $140 million state-of-the-art facility benefit from a long-standing collaboration between Children's Hospital and radiation oncologists at Penn Medicine. Young patients experience family-focused pediatric care from a medical team who understands the unique needs of children with cancer, while providing emotional support for the entire family. Every detail has been considered-- from scheduling morning treatments for children who cannot eat prior to anesthesia, to offering a dedicated child-oriented waiting room and a dedicated pediatric anesthesia room.

source: PR Newswire

Well-Tolerated Radiotherapy Provides Longer Life to Patients With Recurrent Brain Cancer

ScienceDaily (May 24, 2010) — Patients who received hypofractionated stereotactic radiotherapy for their recurrent brain cancers lived longer lives, according to researchers at Thomas Jefferson University.

Not only does hypofractionated stereotactic radiotherapy (H-SRT) provide longer survival, patients do not experience side effects commonly seen with use of chemotherapies and targeted therapies, the researchers found. They believe these findings, reported online in the Journal of Clinical Oncology, set a new bar for the treatment of recurrent gliomas.

"In many centers, patients with tumor progression within six months after the initial conformal radiotherapy are denied a second radiotherapy course (such as H-SRT), based on the assumption that their prognosis is poor." said senior author Maria Werner-Wasik, M.D., professor of Radiation Oncology at Jefferson Medical College of Thomas Jefferson University and Co-Director of the Stereotactic Radiosurgery Program at Jefferson Hospital for Neuroscience. "Our findings support the recommendation that essentially all patients with progressive high-grade gliomas, who are in good shape and have tumors amenable to local radiotherapy, should be considered for H-SRT."

source: Science Daily release

Varian Medical Systems Introduces ProBeam™ Proton Therapy Platform at Particle Therapy Co-operative Group (PT COG) 2010 Meeting

GUNMA, Japan, May 18 /PRNewswire-FirstCall/ -- Varian Medical Systems (NYSE: VAR) is introducing the fully-integrated ProBeam™ proton therapy system at the 2010 Particle Therapy Co-operative Group (PT-COG) meeting here this week. The ProBeam system incorporates imaging, gating, robotic patient positioning, treatment planning and oncology information software to enhance treatment quality for patients and workflow efficiency for clinicians.

"ProBeam is the result of decades of leadership in proton therapy research and development and it has been designed from the ground-up to meet the needs of clinicians and patients alike," says Moataz Karmalawy, head of Varian's particle therapy group. "This fully integrated system can be used for all forms of advanced proton therapy including image-guided proton therapy and intensity-modulated proton therapy."

The ProBeam system incorporates Dynamic Peak™ integrated scanning technology which paints a precise radiation dose on the target volume, enabling true intensity modulated proton therapy. The system also incorporates proprietary pencil-beam scanning technology, which allows for precise dose distribution.

source: Varian

U-M study achieves reduced side effects in head and neck cancer treatment

ANN ARBOR, Mich. — Researchers at the University of Michigan Comprehensive Cancer Center have applied advanced radiation techniques for head and neck cancer to avoid treating critical structures that affect swallowing and eating. A new study shows these principles and techniques treated the cancer effectively while greatly reducing long-term swallowing complications.

The researchers applied highly conformal, intensity-modulated radiation therapy and knowledge of the anatomy and physiology of the structures involved to carefully craft a novel treatment plan that avoids certain muscles in the mouth and throat that are most involved in swallowing. Generally, head and neck tumors do not spread to these structures.

Of the 73 patients treated with this technique, all but four were eating a normal diet after their treatment ended and only one was dependent on a feeding tube. Typically up to 20 percent of head and neck cancer patients remain dependent on a feeding tube after finishing an intensive course of radiation treatment concurrent with chemotherapy.

Results of the study appear online in the Journal of Clinical Oncology.

source: University of Michigan Health System

Experts Discuss the Potential of Stereotactic Body Radiotherapy (SBRT) in the Treatment of Lung, Spine, and Liver Cancer

NEW YORK, April 27 /PRNewswire-FirstCall/ -- Radiosurgical approaches to cancer treatment are showing promise in the treatment of lung, liver, and spinal tumors, according to four leading clinical experts who presented at a symposium in New York earlier this month. New approaches to image-guidance and motion management are making it possible to successfully target tumors that are typically hard to reach with a radiosurgical technique doctors call stereotactic body radiotherapy (SBRT).

"Evidence has shown that increasing the dose to the targeted tumor improves local control or survival, while reducing the dose to normal surrounding tissues reduces treatment toxicity of treatment," said John J. Kresl, M.D., Ph.D., medical director of Radiation Oncologists of Central Arizona at Banner Good Samaritan Medical Center. "This is precisely what stereotactic body radiotherapy enables us to do so well. In the past, outcomes for radiation therapy weren't as good as we hoped for, because side effects prevented us from making the dose high enough to control the cancer. By enabling us to minimize exposure of the normal healthy tissues, stereotactic treatments are helping to overcome this problem."

Radiosurgical treatments involve the use of numerous small, powerful, highly focused radiation beams to attack tumors from many different angles in just one to five sessions. Conventional radiotherapy approaches involve delivering smaller daily doses over 30 to 40 treatment sessions.

source: Varian Medical Systems